Re: Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
作者信息
Atala Anthony
出版信息
J Urol. 2013 Sep;190(3):1132. doi: 10.1016/j.juro.2013.05.071. Epub 2013 Jun 6.
PMID:23931237
Abstract
摘要
相似文献
1
Re: Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.回复：环氧化酶-2（Cox-2）抑制增强舒尼替尼在人肾细胞癌异种移植瘤中的活性。
J Urol. 2013 Sep;190(3):1132. doi: 10.1016/j.juro.2013.05.071. Epub 2013 Jun 6.
2
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.Cox-2 抑制增强了舒尼替尼在人肾细胞癌异种移植瘤中的活性。
Br J Cancer. 2013 Feb 5;108(2):319-26. doi: 10.1038/bjc.2012.591. Epub 2013 Jan 15.
3
Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.智慧之言：关于转移性肾细胞癌中帕唑帕尼与舒尼替尼的比较
Eur Urol. 2014 May;65(5):1014-5. doi: 10.1016/j.eururo.2013.12.042.
4
Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.智慧之言：关于转移性肾细胞癌中帕唑帕尼与舒尼替尼的比较
Eur Urol. 2014 Mar;65(3):667-8. doi: 10.1016/j.eururo.2013.11.023.
5
Pazopanib versus sunitinib in renal cancer.帕唑帕尼与舒尼替尼治疗肾癌的比较
N Engl J Med. 2013 Nov 14;369(20):1969. doi: 10.1056/NEJMc1311795.
6
Pazopanib versus sunitinib in renal cancer.帕唑帕尼与舒尼替尼治疗肾癌的比较
N Engl J Med. 2013 Nov 14;369(20):1969. doi: 10.1056/NEJMc1311795.
7
Pazopanib versus sunitinib in renal cancer.帕唑帕尼与舒尼替尼治疗肾癌的对比
N Engl J Med. 2013 Nov 14;369(20):1968-9. doi: 10.1056/NEJMc1311795.
8
Pazopanib versus sunitinib in renal cancer.帕唑帕尼与舒尼替尼治疗肾癌的比较。
N Engl J Med. 2013 Nov 14;369(20):1970. doi: 10.1056/NEJMc1311795.
9
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.帕唑帕尼与舒尼替尼治疗肾细胞癌的总生存期对比
N Engl J Med. 2014 May 1;370(18):1769-70. doi: 10.1056/NEJMc1400731.
10
Benefits of pazopanib over sunitinib for renal cell carcinoma.帕唑帕尼相对于舒尼替尼治疗肾细胞癌的优势。
Lancet Oncol. 2016 Mar;17(3):e93. doi: 10.1016/S1470-2045(16)00081-4. Epub 2016 Feb 5.
Zotero 插件